Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib-Reference-Cited by-同舟云学术

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib

Published:2020-03 Issue:1 Volume:2 Page:1-10
ISSN:2666-0873
Container-title:JACC: CardioOncology
language:en
Short-container-title:JACC: CardioOncology

Author:

Kunimasa Kei,Kamada Risa,Oka Toru^ORCID,Oboshi Makiko,Kimura Madoka,Inoue Takako,Tamiya Motohiro,Nishikawa Tatsuya,Yasui Taku,Shioyama Wataru,Nishino Kazumi,Imamura Fumio,Kumagai Toru,Fujita Masashi

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Oncology

Reference13 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

2. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

3. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

4. Safety of osimertinib in EGFR-mutated non–small cell lung cancer;Mezquita;Expert Opin Drug Saf,2018

5. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recurrent ventricular arrhythmias and heart failure induced by osimertinib- a case report;Frontiers in Cardiovascular Medicine;2024-08-29

2. Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond;Frontiers in Pharmacology;2024-08-15

3. Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights;Trends in Cancer;2024-08

4. The Interplay Between Cardiovascular Disease and Lung Cancer;Cureus;2024-06-23

5. QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review;Clinical Lung Cancer;2024-06